ADMA Biologics' Revenue Jumps 20% on Strong Product Sales

TL;DR

**ADMA's financials are looking strong with double-digit revenue and profit growth, but keep an eye on that ballooning accounts receivable.**

AI Summary

ADMA Biologics, Inc. reported robust financial performance for the nine months ended September 30, 2025, with total revenues increasing to $371.01 million from $308.91 million in the prior year, marking a 20.1% growth. Net income also saw a significant rise to $97.55 million, up from $85.78 million, representing a 13.7% increase. Gross profit improved to $203.95 million from $156.22 million, reflecting enhanced operational efficiency. The company's cash and cash equivalents decreased to $61.39 million from $103.15 million at December 31, 2024, primarily due to increased investments in property and equipment totaling $21.49 million and treasury stock acquisitions of $23.04 million. Accounts receivable surged to $137.67 million from $49.99 million, indicating strong sales but also a potential increase in collection risk. Inventories grew to $196.67 million from $170.24 million, supporting future sales growth. Strategic outlook includes further commercialization of ASCENIV and BIVIGAM, expansion of manufacturing capacity, and evaluation of new hyperimmune globulins like SG-001.

Why It Matters

ADMA's impressive revenue and net income growth signal strong market acceptance for its IVIG products, ASCENIV and BIVIGAM, which is crucial for investors seeking growth in the biopharmaceutical sector. The increased investment in property and equipment, totaling $21.49 million, suggests a commitment to expanding manufacturing capabilities, potentially enhancing supply chain robustness and competitive positioning against rivals like CSL Behring and Takeda. For patients, this could mean more reliable access to critical treatments for primary immunodeficiency. However, the significant increase in accounts receivable to $137.67 million warrants investor attention, as it could impact future cash flow if collection cycles lengthen, despite the overall positive financial trajectory.

Risk Assessment

Risk Level: medium — The risk level is medium due to the substantial increase in accounts receivable from $49.99 million in December 2024 to $137.67 million in September 2025, representing a 175% jump. While indicative of strong sales, this also increases exposure to credit risk and potential delays in cash collection. Additionally, cash and cash equivalents decreased by $41.76 million, from $103.15 million to $61.39 million, partly due to significant capital expenditures and treasury stock acquisitions, which could limit immediate liquidity for unforeseen operational needs.

Analyst Insight

Investors should consider ADMA's strong revenue and net income growth as a positive indicator of market penetration for its IVIG products. However, closely monitor future filings for trends in accounts receivable collection and cash flow from operations. A sustained increase in accounts receivable without corresponding cash flow improvements could signal underlying issues, despite the otherwise robust top-line performance.

Financial Highlights

revenue

$371.01M

operating Margin

34.7%

total Assets

$568.69M

total Debt

$72.43M

net Income

$97.55M

eps

$0.41

gross Margin

55.0%

cash Position

$61.39M

revenue Growth

+20.1%

Key Numbers

• $371.01M — Total Revenues (Increased from $308.91M in 2024, a 20.1% growth for the nine months ended September 30, 2025.)
• $97.55M — Net Income (Increased from $85.78M in 2024, a 13.7% growth for the nine months ended September 30, 2025.)
• $61.39M — Cash and Cash Equivalents (Decreased from $103.15M at December 31, 2024.)
• $137.67M — Accounts Receivable, net (Increased from $49.99M at December 31, 2024, a 175% increase.)
• $196.67M — Inventories, net (Increased from $170.24M at December 31, 2024.)
• $21.49M — Purchase of property and equipment (Increased from $5.47M in 2024 for the nine months ended September 30, 2025.)
• $23.04M — Acquisition of treasury stock (New activity in 2025, not present in 2024.)
• $0.41 — Basic Earnings Per Common Share (Increased from $0.37 in 2024 for the nine months ended September 30, 2025.)
• $203.95M — Gross Profit (Increased from $156.22M in 2024 for the nine months ended September 30, 2025.)
• $14.76M — Net cash provided by operating activities (Decreased from $68.46M in 2024 for the nine months ended September 30, 2025.)

Key Players & Entities

• ADMA BIOLOGICS, INC. (company) — registrant
• ASCENIV (company) — FDA-approved IVIG product
• BIVIGAM (company) — FDA-approved IVIG product
• Nabi-HB (company) — FDA-approved Hepatitis B Immune Globulin
• FDA (regulator) — U.S. Food and Drug Administration
• Nasdaq Global Market (market) — exchange where ADMA common stock is registered
• ADMA BioManufacturing, LLC (company) — wholly owned subsidiary
• ADMA BioCenters Georgia Inc. (company) — wholly owned subsidiary
• Ares (company) — lender for term loan and revolving facility
• JPM (company) — lender for term loan

FAQ

Industry Context

ADMA Biologics operates in the biopharmaceutical sector, focusing on plasma-derived biologics. The industry is characterized by high R&D costs, stringent regulatory oversight (FDA), and a competitive landscape for sourcing plasma and commercializing specialized therapies. Trends include increasing demand for rare disease treatments and advancements in manufacturing technologies.

Regulatory Implications

As a biopharmaceutical company, ADMA is subject to extensive regulatory scrutiny from bodies like the FDA. Compliance with manufacturing standards (cGMP), product approvals, and post-market surveillance are critical. Any deviations can lead to significant penalties, product recalls, or delays in commercialization, impacting financial performance and market access.

What Investors Should Do

1. Monitor Accounts Receivable Growth
2. Analyze Inventory Levels
3. Evaluate Cash Flow from Operations
4. Assess Capital Allocation Strategy

Glossary

Treasury stock

Shares of a company's own stock that it has repurchased from the open market. These shares are no longer outstanding and do not carry voting rights or pay dividends. (ADMA acquired $23.04 million in treasury stock during the nine months ended September 30, 2025, reducing cash and increasing the number of shares held by the company, which can impact EPS calculations.)

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net profits. It represents the total loss that has not been offset by profits. (ADMA's accumulated deficit decreased from ($308.58M) at December 31, 2024, to ($211.03M) at September 30, 2025, indicating a significant improvement due to net income generated during the period.)

Right-of-use assets

Assets that represent a lessee's right to use an underlying asset for the lease term, recognized under ASC 842 lease accounting standards. (These assets increased from $8.63M to $9.27M, reflecting the company's ongoing lease commitments for facilities or equipment.)

Deferred tax assets, net

Tax assets that result from temporary differences between the book value and tax basis of assets and liabilities, or from tax loss and credit carryforwards. (Deferred tax assets decreased from $84.28M to $74.43M, potentially due to the utilization of tax benefits from current period profits or changes in future taxable income expectations.)

Year-Over-Year Comparison

ADMA Biologics demonstrated strong top-line growth, with total revenues increasing by 20.1% to $371.01M for the nine months ended September 30, 2025, compared to the prior year. Gross profit also saw a substantial improvement, rising to $203.95M, reflecting enhanced operational efficiency. However, cash and cash equivalents decreased by 40.5% to $61.39M, largely due to significant investments in property and equipment and treasury stock acquisitions. A notable concern is the 175% surge in accounts receivable to $137.67M, indicating potential collection challenges, while net cash from operations declined sharply.

Filing Documents

• ef20054948_10q.htm (10-Q) — 1508KB
• ef20054948_ex31-1.htm (EX-31.1) — 10KB
• ef20054948_ex31-2.htm (EX-31.2) — 9KB
• ef20054948_ex32-1.htm (EX-32.1) — 4KB
• ef20054948_ex32-2.htm (EX-32.2) — 4KB
• 0001140361-25-040578.txt ( ) — 7119KB
• adma-20250930.xsd (EX-101.SCH) — 47KB
• adma-20250930_def.xml (EX-101.DEF) — 230KB
• adma-20250930_lab.xml (EX-101.LAB) — 449KB
• adma-20250930_pre.xml (EX-101.PRE) — 249KB
• adma-20250930_cal.xml (EX-101.CAL) — 45KB
• ef20054948_10q_htm.xml (XML) — 1185KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 3 Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 33 Item 4.

Controls and Procedures

Controls and Procedures. 33

OTHER INFORMATION

PART II OTHER INFORMATION 35 Item 1. Legal Proceedings. 35 Item 1A. Risk Factors. 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 64 Item 3. Defaults Upon Senior Securities. 65 Item 4. Mine Safety Disclosures. 65 Item 5. Other Information. 65 Item 6. Exhibits. 66

SIGNATURES

SIGNATURES 67 This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as "ASCENIV ," "Nabi-HB " and "BIVIGAM ," which are protected under applicable intellectual property laws and are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. i Index Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Exchange Act"), and such forward-looking statements involve risks and uncertainties. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions that are not historical facts and typically are identified by use of terms such as "may," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "project," "continue," or the negative thereof, or other variations or comparable terminology, although some forward-looking statements are expressed differently. The forward-looking statements included herein represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. These statements include, among others, statements about: our abil

Financial Statements

Item 1. Financial Statements. ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2025 2024 (Unaudited) (In thousands, except share data) ASSETS Current assets: Cash and cash equivalents $ 61,385 $ 103,147 Accounts receivable, net 137,673 49,999 Inventories, net 196,667 170,235 Prepaid expenses and other current assets 6,930 8,029 Total current assets 402,655 331,410 Property and equipment, net 69,509 54,707 Intangible assets, net 491 460 Goodwill 3,530 3,530 Deferred tax assets, net 74,433 84,280 Right-of-use assets 9,271 8,634 Deposits and other assets 8,798 5,657 TOTAL ASSETS $ 568,687 $ 488,678 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 24,021 $ 20,219 Accrued expenses and other current liabilities 28,827 34,105 Current portion of long-term debt 2,344 - Current portion of lease obligations 1,298 1,218 Total current liabilities 56,490 55,542 Long-term debt 70,084 72,337 Deferred revenue, net of current portion 1,440 1,547 End of term fee - 1,313 Lease obligations, net of current portion 9,397 8,561 Other non-current liabilities 90 360 TOTAL LIABILITIES 137,501 139,660 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Preferred Stock, $ 0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding - - Common Stock - voting, $ 0.0001 par value, 300,000,000 shares authorized, September 30, 2025: 239,661,041 issued and 238,332,393 outstanding; December 31, 2024: 236,620,545 issued and outstanding 24 24 Treasury stock, at cost, 1,328,648 and 0 shares as of September 30, 2025 and December 31, 2024, respectively ( 23,188 ) - Additional paid-in capital 665,382 657,577 Accumulated deficit ( 211,032 ) ( 308,583 ) TOTAL STOCKHOLDERS' EQUITY 431,186 349,018 TOTAL

View Full Filing

View this 10-Q filing on SEC EDGAR